Entrectinib dosage instructions

Drug name: Entrectinib

Drug classification: Targeted therapy drugs

Indications: Enrectinib is a drug used to treat certain types of solid tumors, including tumors carrying NTRK gene fusion mutations, and ROS1positive non-small cell lung cancer (NSCLC).

Medication:

1.Dosage and frequency of administration:

The recommended dose of entrectinib is 600 mg (mg), administered orally once daily.

It is recommended to take it after meals and can be taken with food to reduce the occurrence of digestive tract discomfort.

If a patient experiences serious adverse reactions after taking entrectinib, such as liver function impairment or central nervous system adverse reactions, the doctor may adjust the dose or suspend treatment as appropriate.

2.Dosage form and administration method:

Enrectinib is available in tablet form. Each tablet contains 100mg of the active ingredient entrectinib.

Patients should swallow the tablets whole with a glass of water. Chewing, grinding or splitting the tablets in half is not recommended.

3.Treatment duration:

Treatment with entrectinib should be continued until the patient develops disease progression or is unable to tolerate treatment, or until the physician recommends discontinuing treatment.

4.Medicine for special groups:

For patients with impaired hepatic function, dose adjustment is recommended when initiating treatment.

In patients with impaired renal function, dosage adjustments are generally not required, but monitoring may be necessary in specific circumstances.

5.Combined medication:

The combination of entrectinib and other drugs has not been fully studied clinically, so patients should avoid using it with other drugs while taking entrectinib, unless under the guidance of a doctor.

6.Missing dose:

If a patient misses a dose, the missed dose should be taken as soon as possible before the next dose, but a double dose should not be taken on the same day.

7.Withdrawing and restarting treatment:

If a patient experiences serious adverse reactions, doctors may suspend entrectinib treatment until symptoms resolve or reduce before restarting treatment.

Adverse reactions and warnings:

1.Common adverse reactions of entrectinib include: fatigue, nausea, vomiting, diarrhea, visual disturbances (such as foggy vision, blurred vision), headache, mild liver function abnormalities, central nervous system adverse reactions (such as dizziness, headache, drowsiness, insomnia), etc.

2.Serious adverse reactions may include liver function damage, central nervous system damage (such as memory loss, cognitive impairment, mental status changes), pulmonary toxicity (such as dyspnea, cough, chest pain), etc. These reactions require prompt medical treatment.

Precautions before taking medication:

1.Patients should inform their physician of all allergies, illnesses, and medications they are taking (including prescription drugs, over-the-counter drugs, and supplements) before starting treatment with entrectinib.

2.Enrectinib is contraindicated in pregnancy because it may cause damage to the fetus.

Storage conditions:

Entrectinib should be stored in a cool, dry place away from direct sunlight and away from high temperature and humidity.

The above is a comprehensive description of the medication method of entrectinib. Patients should consult their doctor before receiving treatment with this drug to ensure that they understand the correct medication method, dosage and possible adverse reactions to ensure safe and effective use of the drug.